Skip to main content

Advertisement

Intensive Care Medicine Experimental
Intensive Care Medicine Experimental Cover Image
Download PDF

Report of the first AKI Round Table meeting: an initiative of the ESICM AKI Section

Intensive Care Medicine Experimental volume 7, Article number: 69 (2019) Cite this article

Abstract

Purpose

Critical Care Nephrology is an emerging sub-specialty of Critical Care. Despite increasing awareness about the serious impact of acute kidney injury (AKI) and renal replacement therapy (RRT), important knowledge gaps persist. This report represents a summary of a 1-day meeting of the AKI section of the European Society of Intensive Care Medicine (ESICM) identifying priorities for future AKI research.

Methods

International Members of the AKI section of the ESICM were selected and allocated to one of three subgroups: “AKI diagnosis and evaluation”, “Medical management of AKI” and “Renal Replacement Therapy for AKI.” Using a modified Delphi methodology, each group identified knowledge gaps and developed potential proposals for future collaborative research.

Results

The following key research projects were developed: Systematic reviews: (a) epidemiology of AKI with stratification by patient cohorts and diagnostic criteria; (b) role of higher blood pressure targets in patients with hypertension admitted to the Intensive Care Unit, and (c) specific clearance characteristics of different modalities of continuous renal replacement therapy (CRRT).

Observational studies: (a) epidemiology of critically ill patients according to AKI duration, and (b) current clinical practice of CRRT.

Intervention studies:( a) Comparison of different blood pressure targets in critically ill patients with hypertension, and (b) comparison of clearance of solutes with various molecular weights between different CRRT modalities.

Conclusion

Consensus was reached on a future research agenda for the AKI section of the ESICM.

Introduction

Acute kidney injury (AKI) is common during critical illness and associated with serious short and long-term complications as well as increased use of health care resources [1,2,3,4,5]. Furthermore, managing AKI is a challenge worldwide and one that requires multidisciplinary input [6]. In the last decade, tremendous research efforts have been made and we have vastly improved our understanding of the complexity of AKI but many important questions regarding AKI remain unresolved [7, 8]. For instance, despite the increasing number of epidemiological studies highlighting the incidence and outcomes of AKI, this has not translated into any robust strategies to improve patient-centred outcomes. Undoubtedly, the heterogenous nature of AKI has contributed to the challenges of developing effective therapies.

The AKI section of the European Society of Intensive Care Medicine (ESICM) consists of health care professionals from different countries with a mutual interest in adult critical care nephrology. One of their key objectives is to support research and to facilitate clinical and academic collaborations. This approach has already led to successful funding applications, publications in high-impact journals and ongoing research projects, for instance, AKI-Epi [1], PEACE study (ClinicalTrials.gov Identifier: NCT02341885), REVERSE-AKI (ClinicalTrials.gov Identifier: NCT03251131), and PREV-AKI 2 (ClinicalTrials.gov Identifier: NCT03244514).

Clinical practice remains heterogenous and quality standards are lacking. In recognition of ongoing uncertainties and variation in clinical practice, the ESICM AKI section convened an AKI Round Table (ART) meeting. The objectives of this 1-day meeting were to determine priorities for future AKI research to be conducted under the umbrella of the AKI section. This report represents a summary of the conclusions (Table 1).

Table 1 Summary of research projects proposed by the ART panel
Full size table

Methods

ART panel

The Chairs of the AKI section selected current members to join the first ART Meeting. Nomination was based on expertise and academic track record in the field of AKI and commitment to the AKI section in general. Twelve members were available and accepted the invitation. All participants were experts in the field of Critical Care Nephrology and research active. A core group of 4 members organized the meeting and agreed by consensus that the focus of the meeting should be to identify research topics in the 3 key areas of Critical Care Nephrology: “AKI diagnosis and evaluation”, “Medical management of AKI” and “Renal Replacement Therapy for AKI”. Preceding the meeting, the participants were allocated to one of the three subgroups. The methodology and the structure of the meeting were agreed in advance by the core group and discussed with the participants in order to allow sufficient time for preparation.

ART meeting

The meeting consisted of a one-day workshop which was held in October 2018, 1 day before the annual ESICM congress. Participants were asked to self-fund their attendance. Importantly, there was no involvement or support from commercial companies. The structure of the meeting followed a modified Delphi approach. Following an initial introduction and plenary session outlining the objectives of the meeting, the participants presented the outcome of their pre-meeting work and subsequently worked in their allocated groups and developed potential proposals for future research. During two open panel discussions, each group presented their preliminary and final proposals to the other two groups for feedback, approval, and consensus. All responses and feedback were non-anonymous.

Objectives

The aims of the ART meeting were to identify important areas where evidence and consensus were lacking and clinical practice was variable and to develop projects for future clinical research. Key requirements were that the proposals focussed on clinical aspects, were relevant to the majority of AKI section members and beyond, allowed centres from different countries to participate, and that they met global gaps in knowledge. The groups were encouraged to refer to the intensive care medicine agenda on AKI, as published in 2017 [7]. Each subgroup was asked to consider a systematic review or meta-analysis, an observational cohort study, and a prospective interventional trial, if possible. It was agreed that proposals needed to be pragmatic, multicentre, collaborative, and feasible without the need for extensive funding. There was full agreement that all members of the AKI section would be invited to collaborate and that their contribution would be acknowledged in future publications.

Results

Following detailed review of the existing literature and in-depth discussions, the working groups identified and developed the following proposals:

A. Group 1: Diagnosis and evaluation of AKI

The reported incidence of AKI is highly variable [6]. This heterogeneity might be explained by the definitions used (RIFLE, AKIN or KDIGO criteria), differences in patient populations, case-mix, and clinical setting as well as differences in managing missing data. Furthermore, the current consensus definition of AKI includes the notion of a continuum of disease but there is clear evidence of different sub-categories of AKI, for instance, rapid reversal AKI (duration < 48 h), persistent AKI (duration between 2 and 7 days) and acute kidney disease (up to 90 days). To the best of our knowledge, there are only limited data evaluating the epidemiology and outcomes of patients with AKI of different durations (using current criteria, including AKI stages) [9].

  1. i.

    Proposal for systematic review

Aim: to summarize the existing data related to the epidemiology of AKI with stratification by different patient populations and diagnostic criteria in order to increase granularity

Endpoints: Primary endpoint: overall AKI prevalence; Secondary endpoints: AKI prevalence stratified by diagnostic criteria, population type and management of missing data.

Statistical Analysis: meta-regression and multivariable meta-regression

Criteria for study selection: (a) Publication date after 2012; (b) Publication language: English; (c) Study design: multicentre or > 100 patients recruited from the same center; and (d) Published as a full paper (no abstract)

Search Strategy: Search in Pubmed and Embase using the following MESH criteria: “Acute kidney injury” or “AKI”

  1. ii.

    Proposal for Prevalence Study

Aim: to explore the epidemiology and outcome of critically ill patients according to AKI duration.

Methods: Observational retrospective multicentre prevalence study including 10 to 20 centres.

Eligibility criteria: Inclusion criteria: all patients admitted to a participating ICU during the study period (1 month); Exclusion criteria: end-stage renal disease treated with chronic dialysis or renal transplant

Definitions: AKI will be defined by the KDIGO criteria (> 26.5 μmol/l or 1.5× baseline rise in serum creatinine and/or urine output < 0.5 ml/kg/hr for 6 h) [8]; AKI will be stratified according to the duration of the alteration [persistence of AKI criteria or need for renal replacement therapy (RRT)].

Endpoints: Primary endpoint: prevalence of AKI according to duration category; Secondary endpoints: specific mortality for each AKI duration category and renal recovery at 90 days (absence of AKI criteria and need for RRT)

B. Group 2: Medical management of AKI

To date, the management of AKI patients focuses on correction of the underlying cause, avoidance of further renal insults, strategies to prevent progression to a more severe stage of AKI and if possible, facilitation of renal recovery. A key component of this approach is haemodynamic optimization [8]. However, there is uncertainty about the exact haemodynamic targets.

The current Kidney Disease Improving Global Outcomes (KDIGO) guideline and the ESICM recommendations for “Prevention of acute kidney injury and protection of renal function in the intensive care unit” advise to consider haemodynamic monitoring early and to aim for a mean arterial pressure (MAP) greater than 65 mmHg to prevent AKI [8, 10]. Concern has been raised that this target may be too low for individual patient groups. In patients with septic shock, for instance, a retrospective study concluded that a higher target MAP was associated with better kidney function [11]. Similarly, a sub-group analysis of a randomized controlled trial (RCT) comparing different MAP targets suggested that the rate of RRT in patients with pre-existing hypertension was significantly lower if randomized to the higher blood pressure group [12]. Among patients with vasopressor-dependent shock post-cardiac surgery, those with progression of AKI had a greater difference (deficit) in hemodynamic pressure-related parameters between baseline and within-ICU stay compared to those without AKI progression [13]. Finally, there are also data suggesting that a higher MAP in critically ill patients with early AKI is associated with a reduced risk of progression to more severe AKI [14]. It is our hypothesis that a higher target MAP in critically ill patients with pre-existing hypertension is associated with better renal outcomes.

  1. i.

    Proposal for systematic review and meta-analysis

    Objective: To explore whether a higher target MAP in patients at risk of AKI admitted to ICU with known hypertension is associated with improved outcomes

    Search criteria: a) RCTs only, including indirect data from RCTs; b) published after 2004; c) published in all languages

    Search engines: bibliographic databases (MEDLINE, Embase, Cochrane Library, CINAHL and Web of Science) from January 2004 to January 2018

    Patient population: adult patients (≥18 years) in Critical Care or ICU

    Definitions: a) AKI as defined by RIFLE, AKIN or KDIGO criteria; b) Hypertension as defined by criteria used in the individual studies.

  2. ii.

    Proposal for randomized controlled trial

    Objective: To investigate whether a higher MAP in critically ill patients with known hypertension is renoprotective.

    Patient population: subgroup of critically ill adult patients (i.e. septic shock, post cardiac surgery or trauma; to be determined at later stage)

Eligibility criteria: Inclusion criteria: (a) admitted to a critical care unit; (b) known hypertension (i.e. hypertension treated with at least 1 antihypertensive), and c) expected to stay in ICU for at least 48 h; Exclusion criteria: a) in ICU for > 36 h; b) MAP > 70 mmHg at screening and enrolment without vasopressor support; (c) chronic kidney disease stage 4 or 5; (d) chronically dialysis dependent ESRD; (e) treatment with RRT at time of enrolment; (f) need for ECMO at time of enrolment; (g) any contraindication to higher or lower MAP target

Group allocation and interventions: Standard care: target MAP 65–75 mmHg for at least 48 h after randomization. Intervention group: target MAP 80–90 mmHg for at least 48 h after randomization.

Interventions to achieve MAP target: Traditional strategies, including fluids, vasopressors and/or inotropes as per judgement of clinical team. However, starches should not be used for fluid therapy.

Concomitant treatments: All other aspects of care will be according to local practice and discretion of the treating clinical team. The decision to initiate RRT will be made by the clinical team based on traditional clinical parameters.

Outcomes: Depending on whether patients already have AKI or no AKI at time of randomization:

  1. i.

    In patients without AKI at randomization:

    Primary outcome: prevention of AKI in 7 days; Secondary outcomes: (a) mortality; (b) creatinine at 28 days; (c) Major adverse kidney event (MAKE) at 28 days; (d) hospital length of stay; (e) if AKI develops: duration and severity of AKI, including treatment with RRT; f) adverse events; (g) max dose and duration of catecholamine treatment

  2. ii.

    In patients with AKI at enrolment and no immediate need for RRT at randomization

    Primary outcome: MAKE at 28 days; Secondary outcomes: (a) mortality; (b) creatinine at 28 days; (c) hospital length of stay; (d) duration and severity of AKI; (e) treatment with RRT; (f) adverse events; (g) max dose and duration of catecholamine treatment

Potential challenges: The main limitation is the fact that the intervention strategies to raise MAP and all other concomitant therapies are not standardized. As such, the outcomes may be influenced by factors other than target MAP, for instance choice and volume of fluids, use of nephrotoxic drugs and decision to initiate RRT.

C. Group 3: Renal replacement therapy for AKI

The optimal modality of continuous renal replacement therapy (CRRT) for AKI is unknown and clinical practice is highly variable [15, 16]. To date, precise and exhaustive information about how CRRT is administered worldwide in 2020 is lacking. There is no clear evidence that specific modalities of CRRT are superior to others, and detailed analyses of the effects of CRRT modality on solute clearance are limited [17,18,19,20]. It is assumed that continuous venovenous haemofiltration (CVVH) leads to better clearance of larger molecules compared to continuous venovenous haemodialysis (CVVHD) due to solutes being dragged by the solvent. However, this has not been confirmed [21, 22]. In addition, clearance of larger molecules in CVVH may be impacted with time by clogging related to hemoconcentration inside the filter (depending on the filtration fraction). Lastly, there are no recent data about the clinical effects of convection versus diffusion in CRRT.

  1. i.

    Proposal for systematic review and meta-analysis

Aim: To systematically search and compile the available data focusing on the comparison of CVVH versus CVVHD

Endpoints: Primary endpoint: Solute clearance of various molecules, cytokines and antibiotics; Secondary endpoints: clinical endpoints

Study Selection: (a) studies comparing CRRT with diffusion (CVVHD) versus CRRT with convection (CVVH); (b) published as full papers; (c) published in English

  1. ii.

    Proposal for observational study

Aim: to capture data related to the current clinical practice of CRRT

Design: International survey sent to institutions worldwide (using ESICM research network). Methodology: Questions will be primarily focused on CRRT modality to explore the use of CVVH, CVVHD and CVVHDF. Additional questions will intend to describe how these 3 modalities are administered in daily clinical practice (dose, anticoagulation, timing, type of hemofilter, average filter duration, compulsory change of set every 24 h (yes/no), number of treatment days per year or number of treated patients/year).

  1. iii.

    Proposal for interventional study

Hypothesis: Solute clearance is similar between CVVH and CVVHD, including for middle molecular weight solutes

Aim: To compare clearances of different solutes with various molecular weights between CVVH and CVVHD over 72 h

Inclusion criteria: Critically ill patients undergoing CRRT

Design: Patients will be randomized in two groups, CVVH or CVVHD. CRRT dose and anticoagulation (citrate) will be the same in both groups, based on current KDIGO recommendations [8]. Membranes will be polysulfone-based (e.g. HF1400, AV1000S) with a standard cut-off of 30,000 Da. Solute clearances will be calculated at the following time-points: 1 h, 6 h, 12 h, 24 h, 48 h, 72 h. Cross-over will not be allowed.

Outcomes: Primary outcome: clearance of one large molecular solute (e.g. beta 2 microglobulin); Secondary outcomes: a) time weighted average solute clearances including urea, creatinine, Interleukin-6, tumor necrosis factor (TNF), kappa Free Light Chain (25,000 Da), lambda Free Light Chain (50,000 Da), albumin; b) Metabolic endpoints: acid-base status and electrolyte disturbances; c) Hemodynamic impact endpoint: vasopressor treatment; d) filter life; e) survival at 30 day and hospital discharge; f) CRRT free days; g) Renal recovery: dialysis dependence at hospital discharge; h) filter survival time

Number of patients per group: 60 patients

Additional remarks: the study will only be conducted in centres where both modalities (CVVH and CVVHD) can be delivered in order to minimize potential confounders.

Discussion

The first ART meeting identified and developed key proposals in the fields of epidemiology, medical management and RRT. In Critical Care Nephrology, there is a clear need for larger epidemiological research but also small, well defined studies addressing specific niche aspects, like clearance during CRRT.

The current definition of AKI is very pragmatic but does not account for the heterogeneity of AKI as a syndrome [8]. Instead of describing a specific pathophysiological entity, AKI represents an “umbrella” term for a vast number of conditions characterized by a rise in serum creatinine or decrease in urine output. In addition, important aspects related to AKI, including recurrence and clinical context are not incorporated in the current criteria. Finally, the significance of duration of AKI remains uncertain. This includes short periods of AKI or rapid reversal of AKI, or AKI lasting for 7 days or longer, so called “Acute Kidney Disease” (AKD) [8, 23].

The proposals of the working group on diagnosis and definition of AKI will focus on the epidemiology of AKI in different subgroups of critically ill patients and its etiology and duration. As such, they will explore the epidemiology and outcomes according to the current KDIGO definition and investigate the impact of different patterns and durations of AKI [23]. Especially, the two types “rapid reversal of AKI“ (i.e. duration of 48 h or less) and “AKD” (duration up to 90 days) have not been well explored so far. Finally, the nature of the ESICM AKI network may also allow an investigation of regional differences in the epidemiology of AKI.

To date, the management of AKI remains supportive with focus on correction of volume depletion and hypotension, avoidance of further nephrotoxic insults and treatment of the underlying acute illness. Although this makes sense at first glance, the details for management at the bedside are scarce or lacking [24]. For instance, there is no consensus on the optimal method of assessing volume status, rate of fluid administration, haemodynamic targets to prevent or reverse AKI and the optimal strategy to correct hypotension. Accordingly, the ART panel identified blood pressure as the target of a pragmatic and feasible future intervention study.

Finally, clinical trials in the field of RRT have established that a higher dose of RRT does not translate into better outcomes and that regional anticoagulation with citrate is associated with longer filter life in CRRT. However, other important aspects are still uncertain, for instance the optimal modality, timing and discontinuation of RRT [16, 24]. Despite several decades of applying convective and diffusive RRT modalities, the evidence on its use is very limited. At present, the application of diffusive and convective therapies is mainly driven by pragmatic arguments, and not by evidence. Since clearance is an essential element of RRT, the RRT working group selected this topic for further studies: a literature review, an international survey and a randomized controlled trial. If successful, we believe the results will inform future decision making in Critical Care Nephrology.

It is fully acknowledged that there are many more areas where clinical practice is variable and more evidence is urgently required. The suggested proposals by the ART panel members represent areas of high priority and allow participation and collaboration among all interested ESICM AKI section members and beyond.

In conclusion, the ART panel identified pragmatic and feasible studies that are open to all ESICM AKI section members to participate. These studies cover the entire spectrum of clinical AKI in 3 domains: diagnosis and epidemiology, medical therapy and RRT. Although achieving consensus among experts is already a major achievement, we acknowledge that more work is necessary to develop the relevant protocols further, secure the necessary funding, and recruit collaborators.

The ART meeting was the first of hopefully a series of meetings which aim to develop and facilitate collaborative research to advance the field of Critical Care Nephrology and improve the outcome of patients with AKI.

Availability of data and materials

Not applicable.

References

  1. 1.

    Hoste EA, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, Edipidis K, Forni LG, Gomersall CD, Govil D et al (2015) Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med 41(8):1411–1423

  2. 2.

    Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E et al (2005) Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 294(7):813–818

  3. 3.

    Wu VC, Wu CH, Huang TM, Wang CY, Lai CF, Shiao CC, Chang CH, Lin SL, Chen YY, Chen YM, Chu TS, Chiang WC, Wu KD, Tsai PR, Chen L, Ko WJ, NSARF Group (2014) Long-term risk of coronary events after AKI. J Am Soc Nephrol 25:595–605

  4. 4.

    Wu VC, Wu PC, Wu CH, Huang TM, Chang CH, Tsai PR, Ko WJ, Chen L, Wang CY, Chu TS, Wu KD, National Taiwan University Study Group on Acute Renal Failure (NSARF) Group (2014) The impact of acute kidney injury on the long-term risk of stroke. J Am Heart Assoc 3(4)

  5. 5.

    Collister D, Pannu N, Ye F, James M, Hemmelgarn B, Chui B, Manns B, Klarenbach S, Alberta Kidney Disease Network (2017) Health Care Costs associated with AKI. Clin J Am Soc Nephrol 12(11):1733–1743

  6. 6.

    Hoste EAJ, Kellum JA, Selby NM, Zarbock A, Palevsky PM, Bagshaw SM, Goldstein SL, Cerda J, Chawla LS (2018) Global epidemiology and outcomes of acute kidney injury. Nat Rev Nephrol 14(10):607–625

  7. 7.

    Pickkers P, Ostermann M, Joannidis M, Zarbock A, Hoste E, Bellomo R, Prowle J, Darmon M, Bonventre JV, Forni L et al (2017) The intensive care medicine agenda on acute kidney injury. Intensive Care Med 43(9):1198–1209

  8. 8.

    Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group (2012) KDIGO clinical practice guideline for acute kidney injury. Kidney Int 2:1–138

  9. 9.

    Mehta S, Chauhan K, Patel A, Patel S, Pinotti R, Nadkarni GN, Parikh CR, Coca SG (2018) The prognostic importance of duration of AKI: a systematic review and meta-analysis. BMC Nephrol 19(1):91

  10. 10.

    Joannidis M, Druml W, Forni LG, Groeneveld ABJ, Honore PM, Hoste E, Ostermann M, Straaten O-v, Schetz M (2017) Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017: Expert opinion of the Working Group on Prevention, AKI section, European Society of Intensive Care Medicine. Intensive Care Med 43(6):730–749

  11. 11.

    Dünser MW, Takala J, Ulmer H, Mayr VD, Luckner G, Jochberger S, Daudel F, Lepper P, Hasibeder WR, Jakob SM (2009) Arterial blood pressure during early sepsis and outcome. Intensive Care Med 35(7):1225–1233

  12. 12.

    Asfar P, Meziani F, Hamel JF et al (2014) High versus low blood-pressure target in patients with septic shock. N Engl J Med 370(17):1583–1593

  13. 13.

    Saito S, Uchino S, Takinami M, Uezono S, Bellomo R (2016) Postoperative blood pressure deficit and acute kidney injury progression in vasopressor-dependent cardiovascular surgery patients. Crit Care 20:74

  14. 14.

    Raimundo M, Crichton S, Syed Y, Martin JR, Beale R, Treacher D, Ostermann M (2015) Low systemic oxygen delivery and blood pressure and risk of progression of early acute kidney injury. Clin J Am Soc Nephrol 10(8):1340–1349

  15. 15.

    Ronco C, Ricci Z, De Backer D, Kellum JA, Taccone FS, Joannidis M, Pickkers P, Cantaluppi V, Turani F, Saudan P et al (2015) Renal replacement therapy in acute kidney injury: controversy and consensus. Crit Care 19:146

  16. 16.

    Bagshaw SM, Darmon M, Ostermann M, Finkelstein FO, Wald R, Tolwani AJ, Goldstein SL, Gattas DJ, Uchino S, Hoste EA, Gaudry S (2017) Current state of the art for renal replacement therapy in critically ill patients with acute kidney injury. Intensive Care Med 43(6):841–854

  17. 17.

    Bonnassieux M, Duclos A, Schneider AG, Schmidt A, Bénard S, Cancalon C, Joannes-Boyau O, Ichai C, Constantin JM, Lefrant JY, Kellum JA, Rimmelé T, AzuRéa Group (2018) Renal Replacement Therapy Modality in the ICU and Renal Recovery at Hospital Discharge. Crit Care Med 46(2):e102–e110

  18. 18.

    Wald R, Friedrich JO, Bagshaw SM, Burns KE, Garg AX, Hladunewich MA, House AA, Lapinsky S, Klein D, Pannu NI, Pope K, Richardson RM, Thorpe K, Adhikari NK (2012) Optimal Mode of clearance in critically ill patients with Acute Kidney Injury (OMAKI)--a pilot randomized controlled trial of hemofiltration versus hemodialysis: a Canadian Critical Care Trials Group project. Crit Care 16(5):R205

  19. 19.

    Ricci Z, Ronco C, Bachetoni A, D'amico G, Rossi S, Alessandri E, Rocco M, Pietropaoli P (2006) Solute removal during continuous renal replacement therapy in critically ill patients: convection versus diffusion. Crit Care 10(2):R67

  20. 20.

    Kellum JA, Johnson JP, Kramer D, Palevsky P, Brady JJ, Pinsky MR (1998) Diffusive vs. convective therapy: effects on mediators of inflammation in patient with severe systemic inflammatory response syndrome. Crit Care Med 26(12):1995–2000

  21. 21.

    Chen LX, Demirjian S, Udani SM, Trevino SA, Murray PT, Koyner JL (2018) Cytokine Clearances in Critically Ill Patients on Continuous Renal Replacement Therapy. Blood Purif 46(4):315–322

  22. 22.

    Balgobin S, Morena M, Brunot V, Besnard N, Daubin D, Platon L, Larcher R, Amigues L, Landreau L, Bargnoux AS, Dupuy AM, Cristol JP, Klouche K (2018) Continuous Veno-Venous High Cut-Off Hemodialysis Compared to Continuous Veno-Venous Hemodiafiltration in Intensive Care Unit Acute Kidney Injury Patients. Blood Purif 46(3):248–256

  23. 23.

    Chawla LS, Bellomo R, Bihorac A, Goldstein SL, Siew ED, Bagshaw SM, Bittleman D, Cruz D, Endre Z, Fitzgerald RL, Forni L, Kane-Gill SL, Hoste E, Koyner J, Liu KD, Macedo E, Mehta R, Murray P, Nadim M, Ostermann M, Palevsky PM, Pannu N, Rosner M, Wald R, Zarbock A, Ronco C, Kellum JA, Acute Disease Quality Initiative Workgroup 16 (2017) Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol 13(4):241–257

  24. 24.

    Kashani K, Rosner MH, Haase M, Lewington AJP, O'Donoghue DJ, Wilson FP, Nadim MK, Silver SA, Zarbock A, Ostermann M, Mehta RL, Kane-Gill SL, Ding X, Pickkers P, Bihorac A, Siew ED, Barreto EF, Macedo E, Kellum JA, Palevsky PM, Tolwani AJ, Ronco C, Juncos LA, Rewa OG, Bagshaw SM, Mottes TA, Koyner JL, Liu KD, Forni LG, Heung M, Wu VC (2019) Quality Improvement Goals for Acute Kidney Injury. Clin J Am Soc Nephrol 14(6):941–953

Download references

Acknowledgements

Not applicable.

Ethical approval and consent to participate

Not applicable.

Funding

No funding or financial support was received.

Author information

Affiliations

  1. Department of Critical Care, King’s College London, Guy’s & St Thomas’ Hospital, London, UK
    • M. Ostermann
  2. Adult Intensive Care Unit, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
    • A. Schneider
  3. Department of Anesthesiology and Critical Care Medicine, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France
    • T. Rimmele
  4. Aneszteziológiai és Intenzív Terápiás Klinika, Semmelweis Egyetem, Budapest, Hungary
    • I. Bobek
  5. Department of Intensive Care Medicine, University Medical Center Utrecht, Utrecht, The Netherlands
    • M. van Dam
  6. Medical ICU, Saint-Louis University Hospital, AP-HP, Paris, France
    • M. Darmon
  7. Department of Clinical and Experimental Medicine, Faculty of Health Sciences, University of Surrey and Intensive Care Unit, Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK
    • L. Forni
  8. Service d’Anesthesie-Reanimation SUD, CHU de Bordeaux, Hôpital Magellan, Bordeaux, France
    • O. Joannes-Boyau
  9. Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria
    • M. Joannidis
  10. Department of Anesthesiology and Peri-operative Care, University of California, San Francisco, USA
    • M. Legrand
  11. Critical Care and Perioperative Medicine Research Group, Adult Critical Care Unit, The Royal London Hospital, Barts Health NHS Trust, London, and William Harvey Research Institute, Queen Mary University of London, London, UK
    • J. Prowle
  12. Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany
    • A. Zarbock
  13. Intensive Care Unit, Ghent University Hospital, Ghent University, Ghent, Belgium
    • E. Hoste
  14. Research Foundation-Flanders (FWO), Brussels, Belgium
    • E. Hoste
Authors
  1. M. Ostermann
    View author publications
    You can also search for this author in
  2. A. Schneider
    View author publications
    You can also search for this author in
  3. T. Rimmele
    View author publications
    You can also search for this author in
  4. I. Bobek
    View author publications
    You can also search for this author in
  5. M. van Dam
    View author publications
    You can also search for this author in
  6. M. Darmon
    View author publications
    You can also search for this author in
  7. L. Forni
    View author publications
    You can also search for this author in
  8. O. Joannes-Boyau
    View author publications
    You can also search for this author in
  9. M. Joannidis
    View author publications
    You can also search for this author in
  10. M. Legrand
    View author publications
    You can also search for this author in
  11. J. Prowle
    View author publications
    You can also search for this author in
  12. A. Zarbock
    View author publications
    You can also search for this author in
  13. E. Hoste
    View author publications
    You can also search for this author in

Contributions

MO wrote the first draft of the manuscript. All authors reviewed the draft and made contributions. The final draft was approved by all authors.

Authors’ information

All authors are experts in critical care nephrology and members of the AKI section of the ESICM.

Corresponding author

Correspondence to M. Ostermann.

Ethics declarations

Consent for publication

Not applicable.

Competing interests

AS has received speaker honoraria from Fresenius Medical Care, B Braun Avitum and Cytosorbents SA. EH has received speaker’s fees from Alexion, Sopachem and Astute Medical, and travel support from AM Pharma. MJ has received honoraria and research support from Baxter Healthcare Corp, AM Pharma, CLS Behring, Fresenius and Astute Medical. ML has received lecture fees from Baxter and Fresenius Medical, research support from Sphingotech and consulting fees from Novartis. MO has received speaker honoraria and research funding from Fresenius Medical Care and Baxter.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ostermann, M., Schneider, A., Rimmele, T. et al. Report of the first AKI Round Table meeting: an initiative of the ESICM AKI Section. ICMx 7, 69 (2019). https://doi.org/10.1186/s40635-019-0280-z

Download citation